United States

Acceleron Pharma Inc (XLRN.O)

XLRN.O on Consolidated Issue listed on NASDAQ Global Market

27 Feb 2017
Change (% chg)

$1.48 (+5.88%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for XLRN.O


Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates... (more)


Beta: 1.70
Market Cap(Mil.): $950.08
Shares Outstanding(Mil.): 37.75
Dividend: --
Yield (%): --


  XLRN.O Industry Sector
P/E (TTM): -- 44.08 29.63
EPS (TTM): -1.79 -- --
ROI: -33.04 -3.35 12.96
ROE: -35.87 5.80 14.11

BRIEF-Acceleron outlines corporate goals and priorities for 2017

* Plan to initiate new luspatercept phase 2 clinical trials in distinct patient segments in MDS and Beta-Thalassemia

Jan 06 2017

BRIEF-Acceleron Pharma reports Q3 financial and operational results

* Acceleron Pharma reports third quarter 2016 financial and operational results Source text for Eikon: Further company coverage:

Nov 03 2016

U.S. RESEARCH ROUNDUP-Alkermes, Chesapeake Energy Corp, Latam Airlines

Oct 21 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alkermes, Benchmark Electronics and Copa Holdings on Friday. HIGHLIGHTS * Chesapeake Energy Corp : Nomura raises to neutral from reduce * Latam Airlines : Santander raises to buy from hold * Proofpoint Inc : Piper Jaffray raises target price to $90 from $85; overweight Following is a sum

Oct 21 2016

More From Around the Web

Earnings vs. Estimates